Jorge A. Sánchez-Duque
Grupo México
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jorge A. Sánchez-Duque.
Primary Care Diabetes | 2017
Andrés Gaviria-Mendoza; Jorge A. Sánchez-Duque; Diego Alejandro Medina-Morales; Jorge Enrique Machado-Alba
AIMS To determine the prescription patterns of antidiabetic medications and the variables associated with their use in a Colombian population. METHODS A cross-sectional study using a systematized database of approximately 3.5 million affiliates of the Colombian Health System. Patients of both genders and all ages treated uninterruptedly with antidiabetic medications for three months (June-August 2015) were included. A database was designed that included sociodemographic, pharmacological, comedication, and cost variables. RESULTS A total of 47,532 patients were identified; the mean age was 65.5 years, and 56.3% were women. Among the patients, 56.2% (n=26,691) received medication as monotherapy. The most prescribed medications were metformin, 81.3% (n=38,664), insulins, 33.3% (n=15,848), and sulfonylureas, 21.8% (n=10,370). Among the patients, 92.8% received comedications, including antihypertensives (79.7%), hypolipemiants (65.5%), antiplatelet drugs (56.3%), analgesics (33.9%), antiulcerants (33.1%), and thyroid hormone (17.3%). The cost per 1000 inhabitants/day was
Investigación en Educación Médica | 2017
Jorge A. Sánchez-Duque; José F. Gómez-González; Alfonso J. Rodriguez-Morales
1.21 USD for metformin,
Reumatología Clínica | 2017
Alfonso J. Rodriguez-Morales; Jorge A. Sánchez-Duque; Juan-Manuel Anaya
3.89 USD for insulins, and
Revista chilena de neuro-psiquiatría | 2018
Carolina Jaramillo-Toro; José William Martínez; José F. Gómez-González; P Tanya Mesa; Sebastián Otálvaro; Jorge A. Sánchez-Duque
0.02 USD for glibenclamide. CONCLUSIONS Generally, rational prescription habits predominated, however in some cases an overuse of comedications (such as antiulcer drugs) and a large group of patients with high cost formulations were observed. Subsequent effectiveness and cost-benefit analyzes are required.
Archive | 2018
Alfonso J. Rodríguez-Morales; Adriana M. Trujillo; Jorge A. Sánchez-Duque; Jaime A. Cardona-Ospina; Wilmer E. Villamil-Gómez; CarlosE. Jimenez-Canizalez; Jorge L. Alvarado-Socarras; Juan CarlosSepúlveda-Arias; Pío López; Matthew H. Collins; Alberto E. Paniz-Mondolfi; Antonio Carlos Bandeira; José Antonio Suárez
Archive | 2018
Jorge A. Sánchez-Duque; Alfonso J. Rodríguez-Morales; Adriana M. Trujillo; Jaime A. Cardona-Ospina; Wilmer E. Villamil-Gómez
Discover Medicine | 2018
Jorge A. Sánchez-Duque; Ricardo Betancourt-Quevedo; Andrés F. García-Zuluaga; Camila A. Viveros-Moreno
Revista Hispanoamericana de Ciencias de la Salud (RHCS) | 2017
Jorge A. Sánchez-Duque; Mariana Blanco-Betancur; Samir A. Pantoja-Meneses; Juanita Pérez-Gutiérrez; Andrés M. Patiño-Barbosa; José F. Gómez-González
Revista Hispanoamericana de Ciencias de la Salud | 2017
Jorge A. Sánchez-Duque; Paola A Méndez-Hernández; G. Alejandra Mendieta; Juan S Rodríguez; José F. Gómez-González
Journal of Preventive Epidemiology | 2017
Alfonso J. Rodriguez-Morales; Jorge A. Sánchez-Duque